Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenerative Medical Technology (RMTG) Revenue (2018 - 2025)

Historic Revenue for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to $1.2 million.

  • Regenerative Medical Technology's Revenue rose 1969.22% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 5687.55%. This contributed to the annual value of $4.1 million for FY2024, which is 7043.88% up from last year.
  • Regenerative Medical Technology's Revenue amounted to $1.2 million in Q3 2025, which was up 1969.22% from $983518.0 recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Revenue ranged from a high of $1.5 million in Q4 2024 and a low of $4443.0 during Q1 2021
  • Over the past 5 years, Regenerative Medical Technology's median Revenue value was $615568.0 (recorded in 2023), while the average stood at $632313.2.
  • Over the last 5 years, Regenerative Medical Technology's Revenue had its largest YoY gain of 927413.73% in 2021, and its largest YoY loss of 6075.09% in 2021.
  • Over the past 5 years, Regenerative Medical Technology's Revenue (Quarter) stood at $252633.0 in 2021, then surged by 124.14% to $566256.0 in 2022, then grew by 8.71% to $615568.0 in 2023, then soared by 145.44% to $1.5 million in 2024, then dropped by 21.86% to $1.2 million in 2025.
  • Its Revenue was $1.2 million in Q3 2025, compared to $983518.0 in Q2 2025 and $1.4 million in Q1 2025.